Media Pack
News

Current Edition

JCS Volume 15 Issue 3
 
Regional News

Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe

For years, drugmakers have targeted "weaknesses" in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The "outra...
13 December 2021 Regional News diabetes | drug costs
Continue Reading →
Regional News

Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze

On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign companies Novo Nordisk, Sanofi...
1 December 2021 Regional News china | drug prices
Continue Reading →
Regional News

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It's official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi's blockbuster diabetes m...
17 November 2021 Regional News Biocon | biosimilar
Continue Reading →
Europe

Significant blood sugar improvement with Xultophy® compared to insulin glargine U-100 when used as add-on to oral diabetes medications

Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaem...
27 June 2018 Europe blood | compared
Continue Reading →
news

Sanofi’s Toujeo® met main objective in head-to-head study versus insulin degludec

Sanofi's Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, comparing Toujeo with insulin degludec. Sanofi ...
6 December 2017 news BRIGHT study | clinical trial
Continue Reading →
news

Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial

Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). Thi...
5 December 2017 news clinical trial | diabetes
Continue Reading →
news

Imcyse continues patient enrolment in its Phase 1b trial in type 1 diabetes

Imcyse, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, today announces that it began recruiting patients i...
15 November 2017 news clinical | diabetes
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte